Home
Storia in 1 fonti
Fierce Pharma Asia—Roche’s $2.5B obesity deal; Akeso CEO’s defense; Lawmaker’s reflection on China
With a potential $2.5 billion deal with Hanmi, Roche is taking a less-trodden path in obesity. | Roche is taking a less-trodden path in obesity. Akeso CEO counters concerns over shrinking lung cancer data for ivonescimab. A U.S. congressman says China is "beating us on our ground game" in biotech. Plus more.
Raccontata da
fiercepharma.com
Timeline cronologica
- ·
Akeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debate
Fresh off a phase 3 win in biliary tract cancer, Akeso CEO Michelle Xia, Ph.D., is touting the PD-1xVEGF bispecific antibody ivonescimab’s ability beyond non-small cell lung…
- ·
Amgen, AZ’s Tezspire lands phase 3 eosinophilic esophagitis win, turning up heat on Dupixent
Amgen and AstraZeneca’s inflammatory disease drug Tezspire has clinched
- ·
Fierce Pharma Asia—Roche’s $2.5B obesity deal; Akeso CEO’s defense; Lawmaker’s reflection on China
With a potential $2.5 billion deal with Hanmi, Roche is taking a less-trodden path in obesity. | Roche is taking a less-trodden path in obesity. Akeso CEO counters concerns over…